Tagged with

Korea Antimicrobial resistance (AMR) is a global health concern that we are increasingly understanding the consequences of and pulling together to try and keep under control. Korea is one of the many countries known for their misuse of antibiotics but now it looks as though the country is ready to join…

Turkey Uğur Bingöl, general manager of Ibrahim Etem Menarini, speaks of his company’s rapid growth and new product lines. He also describes his take on the Turkish pharmaceutical market and outlines his strategic priorities to continue growing Ibrahim Etem Menarini’s presence in Turkey.   We are committed to the localization movement…

IFPMA Last week, the IFPMA released their new Code of Practice with the aim of encouraging complete integrity and ethical responsibility within the pharmaceutical industry. We do not want anything to even potentially suggest that we are trying to get between the healthcare professional and the patient at the time of…

Opinion Axel Schumacher, co-founder and chief scientific officer of Shivom, a data-driven next generation precision-medicine company in the blockchain space, calls for Pharma to leverage big-data on a global level to ensure all patients have a therapy option.    The key to success for pharma players is to sponsor the accumulation of…

Korea Paul Henry Huibers, president of Lilly Korea discusses Lilly’s strong double-digit growth following a challenging period of restructuring. Huibers offers his opinion on the pricing difficulties within the Korean market, emphasizing the importance of volume over price. He also concludes that Korea should focus on establishing itself as a leader…

Mexico David Peña Castillo, president and founder of the Mexican Federation of Rare Diseases (FEMEXER), addresses the problem of patients deserting therapies.   In Mexico, approximately 15 percent of patients treated with therapies for rare diseases, dismiss the concept of adherence to treatments. In Latin American Countries such as Mexico, keeping…

Korea The South Korean government has designated the promotion of artificial intelligence (AI)-based drug development and healthcare innovation as a national priority. This new policy aims to capitalise on Korea’s advanced technologies to drive the nation’s economic growth as well as better care for patients at home and abroad.   For…

Spain Luis Serrano, president of the Centre for Genomic Regulation (CRG) in Spain, gives an update on the Centre’s recent history and outlines the need for greater understanding of science and research within the Spanish political class.   When we enter discussions with the different political parties, I feel things are…

France Jean-Luc Belingard, president of FEFIS (Fédération Française des Industries de Santé – French Federation of the Health Industry), explains his role following up on the implementation of the CSIS (Conseil stratégique des industries de santé – Strategic council of the healthcare industry) and speaks out about the competitiveness of the…

Spain Carlos Rubió, executive president of Laboratorios Rubió, gives an overview of the company’s early years and his priorities now to make the company a larger player on the international scene. Furthermore, he highlights the need to increase the company´s size through JVs, possible M&As and US expansion, as well as…

Korea Uloff Münster, general manager of Merck Biopharma Korea provides his insights into the Korean healthcare system. Dr Münster also discusses the drug pricing situation in Korea and the potential for companies like Merck to utilize local partnerships.   We are in the process of preparing launches of our new molecules…

Spain Jordi Naval, CEO of Biocat, describes the evolution of the BioRegion of Catalonia as an increasingly relevant biotechnology hub in Spain and Europe. Naval also elaborates on the role of Biocat in tackling the challenge of translating basic research into functional innovation which can impact the healthcare ecosystem.   Now,…